Integragen Operating Margin from 2010 to 2026
| ALINT Stock | EUR 0.18 0.01 5.88% |
Check Integragen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integragen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 96.8 K, Interest Expense of 4.2 K or Selling General Administrative of 3.1 M, as well as many indicators such as Price To Sales Ratio of 0.48, Dividend Yield of 0.0 or PTB Ratio of 2.37. Integragen financial statements analysis is a perfect complement when working with Integragen Valuation or Volatility modules.
Integragen | Operating Margin |
Evaluating Integragen's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Integragen's fundamental strength.
Latest Integragen's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Integragen over the last few years. It is Integragen's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Integragen's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.53) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Integragen Operating Margin Regression Statistics
| Arithmetic Mean | (0.27) | |
| Coefficient Of Variation | (112.90) | |
| Mean Deviation | 0.22 | |
| Median | (0.17) | |
| Standard Deviation | 0.30 | |
| Sample Variance | 0.09 | |
| Range | 1.1682 | |
| R-Value | 0.82 | |
| Mean Square Error | 0.03 | |
| R-Squared | 0.67 | |
| Significance | 0.000065 | |
| Slope | 0.05 | |
| Total Sum of Squares | 1.44 |
Integragen Operating Margin History
About Integragen Financial Statements
Integragen shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Integragen investors may analyze each financial statement separately, they are all interrelated. The changes in Integragen's assets and liabilities, for example, are also reflected in the revenues and expenses on on Integragen's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. IntegraGen SA was founded in 2000 and is headquartered in vry, France. INTEGRAGEN operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 43 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.